Total Funding
32
1
Total FundingGrant raised
Growth Score
-5 pts
Heat Score
-10 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
3845060
Prosensa provides RNA-based therapeutics for the treatment of genetic disorders, infections and cancers.
Acquired by 
BioMarin Pharmaceutical
Daan Ellens: Supervisory Board memberPast Role: Rhein biotech NV, Chief Executive Officer- Judith van Deutekom: Vice-President Drug Discovery
About the Company
Prosensa is a biotech company also known as Ribpharm Inc dedicated to the commercialization of products for the healthcare market based on RNA-based therapeutics.
During the development of this technology, it became clear that many opportunities exist for the development of these products into novel commercially attractive products. These
products are mainly in the field of genetic disorders, anti-infectives and oncology.
Prosensa will focus to maximize the commercial development of the current program, and take advantage of the large novel market opportunities supported by a strong IP position. Prosensa will initially operate mainly as a focussed company, outsourcing most of its activities to specialized organizations.
